Inhalation of Sodium Pyruvate to Reduce the Symptoms and Severity of Respiratory Diseases Including COVID-19, Long COVID, and Pulmonary Fibrosis

Abstract

Background: To combat the continuing COVID-19 pandemic, and to treat the symptoms in Long COVID patients safe, effective, and inexpensive treatments are needed. Patients recovering from severe COVID-19 are at serious risk of de veloping pulmonary fibrosis. Conversely, patients with pulmonary fibrosis have an increased risk and susceptibility to COVID-19 infection, demonstrating the need to treat both. Design: Three separate clinical trials were conducted 1) in COVID-19 infected patients, 2) in Long COVID patients, and 3) in patients with Pulmonary Fibrosis to determine the effi cacy of N115, a sodium pyruvate based nasal spray. Patient symptoms, vital signs and respiratory function were evaluated compared to a placebo control or a no treatment baseline control. Findings: During active COVID-19 infection, N115 de creased viral titers and produced a significant improvement over saline in coughing/sneezing and fatigue. In Long COVID patients, N115 significantly reduced headache, coughing/sneezing and increased SaO2 levels (decreased hypoxemia) and improved breathing (dyspnea). In patients with Pulmonary Fibrosis, there was a significant improvement in all lung func -tions, compared to baseline, as determined by changes in SaO2, FVC, FEV1, PEF, and FEV1/FVC ratio. Conclusions: N115 is safe and effective at reducing symptoms of active COVID-19 infection and improves disease condition in Long COVID patients. Furthermore, N115 significantly improves lung function in Pulmonary Fibrosis patients. As COVID-19 and Pulmonary Fibrosis are associated with each other, our clinical research demonstrates that N115 is a promising treat ment for both and adds to the current 19 human clinical trials where N115 has shown efficacy in thousands of patients, regardless of the etiology of the lung disease (COPD, CF, allergic rhinitis, sinusitis, the flu, COVID-19 infected patients, Long COVID and patients with Fibrosis).